Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

In January 2009, ThromboGenics started the Phase III clinical program of microplasmin for the non-surgical treatment of back of the eye disease. Patient recruitment in this Phase III program is going well and a review by the independent Data Monitoring Committee (DMC) in June led to no changes in the protocols of the two pivotal trials. ThromboGenics expects to be able to report results of these studies from mid of 2010 onwards.

The microplasmin Phase III program comprises two clinical trials, one taking place in the United States (TG-MV-006 trial) and a second combined European/US study (TG-MV-007 trial). The indication for both of these Phase III microplasmin trials is the non-surgical treatment of focal vitreomacular adhesion. Vitreomacular adhesion is a condition in which the vitreous has an abnormally strong adhesion to the retina at the back of the eye. These adhesions can cause vessel and retinal distortion which results in deterioration in the patient's vision. Both of these trials, which will each recruit 320 patients, are using 125ÿ¼g of microplasmin.

Given the good progress that is being made with the Phase III program, ThromboGenics is now starting the initial activities needed to ensure the successful commercialization of this exciting product. Market research is being initiated to provide a clear understanding of how patients with back of the eye diseases are treated. This will provide the detailed market knowledge needed to commercialize the product.

It is ThromboGenics' intention that, if successful, the Company would take this unique product further using its own resources. This is due to the very promising data that the Company has generated to date, the limited competition, and the large potential market for microplasmin with a focused prescribing group. Preliminary market research conducted by the Company suggests that this can be addressed by the small focused commercial
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... researchers from the University of Leicester has furthered ... the potential to create new materials using nanosized ... published in the prestigious academic journal Physical ... to examine in rich detail the structure and ... an acetylene molecule and a single helium atom. ...
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, today announced financial results for the ... 2014 Financial Summary: , Reported cash and cash ... with $137,000 at December 31, 2013.  , Reported ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... (Nasdaq: NKTR ) today reported its financial results ... Cash, cash equivalents, and short-term investments at March 31, 2011 ... 31, 2010. Revenue for the first quarter ... million in the first quarter of 2010.  This decrease in ...
... 2011 GeoVax Labs, Inc. (OTCBB: GOVXD) , a ... today announced its financial results for the three months ended ... of $606,282 for the three months ended March 31, 2011, ... losses were partially offset by grant revenues of $893,002 and ...
... 2011 BSI Group America Inc., a leading ... announces the launch of Specialized Regulatory Training courses ... on-site, these Specialized Regulatory Courses reflect requirements of ... enabling attendees to comply efficiently with regulations in ...
Cached Biology Technology:Nektar Therapeutics Reports First Quarter 2011 Financial Results 2Nektar Therapeutics Reports First Quarter 2011 Financial Results 3Nektar Therapeutics Reports First Quarter 2011 Financial Results 4Nektar Therapeutics Reports First Quarter 2011 Financial Results 5Nektar Therapeutics Reports First Quarter 2011 Financial Results 6Nektar Therapeutics Reports First Quarter 2011 Financial Results 7GeoVax Labs, Inc. Announces First Quarter Financial Results 2GeoVax Labs, Inc. Announces First Quarter Financial Results 3GeoVax Labs, Inc. Announces First Quarter Financial Results 4BSI Group America Inc. Announces Specialized Regulatory Training Courses for the Healthcare Industry 2BSI Group America Inc. Announces Specialized Regulatory Training Courses for the Healthcare Industry 3BSI Group America Inc. Announces Specialized Regulatory Training Courses for the Healthcare Industry 4
(Date:7/27/2014)... has revealed that nicotine and cotinine, a metabolite of ... certain carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or ... and ultimately ends up in the tobacco smoke. Once ... where it is activated by a variety of enzymes ... revealed that nicotine can partially interfere with the activation ...
(Date:7/27/2014)... have shown the potential for global climate change to ... most part, ignored the interactions between increasing temperature and ... to damage crops. , A new study involving researchers ... significant, suggesting that policymakers need to take both warming ... , The study looked in detail at global production ...
(Date:7/25/2014)... of people lived on the land now called California, ... the availability of plants they used for food, fuel, ... to maintain desired habitat and natural resources. , Frank ... Southwest Station, will lead a field trip ... Ecological Society of America,s 99th Annual Meeting, in Sacramento, ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... Previous studies have established that carbon binds to tiny mineral ... , researchers have shown that the surface of the minerals ... carbon binds to minerals that are just a few thousandths ... almost exclusively on rough and angular surfaces," explains Prof. Ingrid ...
... USA New Geology postings extend the understanding ... erosion rates for exposure of today,s southern Rocky ... mudstones "so complicated as to almost defy understanding"; ... rocks on Earth; postulate that biomarkers heat up ...
... research published in the November issue of Nutrition Journal ... lunch may have helped healthy, overweight people feel more satisfied ... The study was funded by the Hass Avocado Board. ... the Effect of Hass Avocado Intake on Post Ingestive Satiety, ...
Cached Biology News:Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 2Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 3Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 4Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 5Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 6Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 7Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 8Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 9New research: Effects of eating half an avocado with lunch on satiety & desire to eat between meals 2
... This CLS number is a new ... product number. If showing no availability yet, ... (Z71,369-4) or contact customer service for assistance. ... Comp Dim: D H 100 ...
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
...
... 5-OxoETE-d7 is used as an internal ... stable isotope dilution mass spectrometry. 5-OxoETE is ... oxidation of 5-HETE in human neutrophils. It ... an EC50 of 2 nM. 5-OxoETE selectively ...
Biology Products: